White Paper: The Benefit Assessment of New Metastatic Breast Cancer (MBC) Treatments

A number of organizations – the University of Catania Medical School, Breast Cancer Network Australia (BCNA), European Society of Breast Cancer Specialists, Europa Donna, European Patients’ Academy (EUPATI), Champalimaud Clinical Center, Karolinska Institutet, Andalusian School of Public Health, Canadian Breast Cancer Network (CBCN), and Lilly – have together published a white paper entitled “The Benefit Assessment of New Metastatic Breast Cancer (MBC) Treatments”. It builds on the multi-stakeholder collaboration, A Policy Roadmap on Addressing Metastatic Breast Cancer, published in 2017.

The new white paper centers on two areas: the challenges in the overall benefit assessment of new MBC treatments; and the role of multi-stakeholder collaboration in MBC decision-making. Moreover, it provides a series of policy recommendations for government agencies, HTA decision-makers and payers, and for MBC multi-stakeholder groups respectively.

The two over-arching policy recommendations in the report are:

  1. To include MBC-specific patient priorities and outcomes in the overall benefit assessment of new MBC treatments
  2. To enhance multi-stakeholder collaboration in order to improve MBC patient outcomes

View the full white paper and set of recommendations here.

https://s3.eu-central-1.amazonaws.com/lillypad-eu/WP/wp-content/uploads/Lilly-neuron.png
https://s3.eu-central-1.amazonaws.com/lillypad-eu/WP/wp-content/uploads/WWR-picture.jpg